The targeting of VEGF using neutralizing mAb, bevacizumab was also effective at inhibiting tumour growth of xenografts derived from CD133+ glioma-initiating cells or U87 glioma cells by decreasing the number of self-renewing and vessel-associated CD133+/nestin+ tumour cells [141, 149]. The gene discussed is NES; the disease is glioma.